US2007010500A1PendingUtilityA1

Prevention of ovarian cancer by administration of a vitamin D compound

62
Individually held — no corporate assignee on recordPriority: Sep 13, 1996Filed: May 26, 2006Published: Jan 11, 2007
Est. expirySep 13, 2016(expired)· nominal 20-yr term from priority
Inventors:Gustavo RodriguezRegina Salas Whitaker
A61K 31/593A61K 31/56A61K 31/565A61K 31/57A61K 31/59
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical product that is contraceptively effective comprising 28 daily sequential dosages, said product including 21 sequential daily hormone dosages, with each hormone dosage comprising a progestin product and an estrogen product and with at least one of said hormone dosages further comprising a Vitamin D compound, and said product further including 7 other daily dosages that do not contain either estrogen and/or progestin.  
     
     
         2 . The product of  claim 1  wherein the Vitamin D compound is 1,25 (OH)2 Vitamin D 3  (calcitriol).  
     
     
         3 . The product of  claim 1  wherein the Vitamin D compound is Vitamin D 3  (cholecalciferol).  
     
     
         4 . The product of  claim 1  wherein said the estrogen product is ethinyl estradiol.  
     
     
         5 . The product of  claim 4  wherein the daily dosage of said ethinyl estradiol is less than or equal to 0.050 mg and greater than or equal to 0.020 mg.  
     
     
         6 . The product of  claim 1  wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 2000 I.U.  
     
     
         7 . The product of  claim 1  wherein said progestin product is norgestimate.  
     
     
         8 . The product of  claim 1  wherein said the estrogen product is ethinyl estradiol and the daily dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.  
     
     
         9 . A pharmaceutical composition comprising a progestin product and a Vitamin D compound that does not have hydroxylation at both the 1 and 25 positions.  
     
     
         10 . The composition of  claim 9  wherein said progestin product and said Vitamin D compound are combined in a single unit dosage.  
     
     
         11 . The composition of  claim 9  wherein the daily dosage equivalent of said progestin product is less than 1.25 mg of norethindrone.  
     
     
         12 . The composition of  claim 9  wherein the Vitamin D compound is Vitamin D 3  (cholecalciferol).  
     
     
         13 . The composition of  claim 9  wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.  
     
     
         14 . The composition of  claim 9  wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.  
     
     
         15 . The composition of  claim 9  wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.  
     
     
         16 . The composition of  claim 9  wherein said progestin product is a gonane.  
     
     
         17 . The composition of  claim 9  where said composition further comprises an estrogen product.  
     
     
         18 . The composition of  claim 9  where the estrogen is ethinyl estradiol.  
     
     
         19 . The composition of  claim 18  wherein the dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.  
     
     
         20 . A pharmaceutical composition comprising a Vitamin D compound and a gonane progestin product.  
     
     
         21 . The composition of  claim 20  wherein said progestin product and said Vitamin D compound are combined in a single unit dosage.  
     
     
         22 . The composition of  claim 20  wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.  
     
     
         23 . The composition of  claim 20  wherein the daily dosage equivalent of said progestin product is less than 1.25 mg of norethindrone.  
     
     
         24 . The composition of  claim 20  wherein the Vitamin D compound is calcitriol.  
     
     
         25 . The composition of  claim 20  wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.  
     
     
         26 . The composition of  claim 20  where said composition further comprises an estrogen product.  
     
     
         27 . The composition of  claim 20  where the estrogen is ethinyl estradiol.  
     
     
         28 . A pharmaceutical product comprising 21 sequential daily dosages, said 21 daily dosages comprising a progestin product and/or an estrogen product, with at least one of said daily dosages further comprising a Vitamin D compound that does not have hydroxylation at both the 1 and 25 positions.  
     
     
         29 . The product of  claim 28  wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.  
     
     
         30 . The product of  claim 28  wherein said estrogen product is conjugated equine estrogen.  
     
     
         31 . The product of  claim 30  wherein the dosage of said conjugated equine estrogen 0.625 mg.  
     
     
         32 . The product of  claim 28  wherein said Vitamin D compound is Vitamin D 3  (cholecalciferol).  
     
     
         33 . The product of  claim 28  wherein said Vitamin D compound is Vitamin D 2  (ergocalciferol).

Join the waitlist — get patent alerts

Track US2007010500A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.